CureVac (NASDAQ:CVAC) Shares Down 6.3%

Shares of CureVac (NASDAQ:CVAC) fell 6.3% during trading on Tuesday . The company traded as low as $2.95 and last traded at $2.95. 478,839 shares traded hands during mid-day trading, a decline of 40% from the average session volume of 802,240 shares. The stock had previously closed at $3.15.

CureVac Stock Performance

The stock’s 50 day simple moving average is $3.41 and its 200 day simple moving average is $4.81. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.56 and a quick ratio of 3.41.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Vontobel Holding Ltd. grew its position in shares of CureVac by 3.8% during the 1st quarter. Vontobel Holding Ltd. now owns 19,411 shares of the company’s stock worth $381,000 after buying an additional 702 shares in the last quarter. Geode Capital Management LLC grew its holdings in CureVac by 0.7% during the 1st quarter. Geode Capital Management LLC now owns 167,202 shares of the company’s stock worth $1,165,000 after acquiring an additional 1,188 shares in the last quarter. Citigroup Inc. increased its position in CureVac by 10.2% during the 2nd quarter. Citigroup Inc. now owns 13,491 shares of the company’s stock valued at $141,000 after purchasing an additional 1,253 shares during the period. Royal Bank of Canada raised its holdings in shares of CureVac by 13.0% in the 3rd quarter. Royal Bank of Canada now owns 11,119 shares of the company’s stock valued at $87,000 after purchasing an additional 1,280 shares in the last quarter. Finally, Marshall Wace LLP lifted its position in shares of CureVac by 0.5% in the 3rd quarter. Marshall Wace LLP now owns 333,819 shares of the company’s stock worth $2,629,000 after purchasing an additional 1,758 shares during the period. 17.26% of the stock is currently owned by hedge funds and other institutional investors.

About CureVac

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.